The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05561569` - Air Versus Gas Tamponade in Primary Retinal Detachment	N/A
Not yet recruiting	`NCT05538156` - Internal Limiting Membrane Peeling in Retinal Detachment Surgery	N/A
Completed	`NCT01445028` - Isotretinoin for Proliferative Vitreoretinopathy	Phase 4
Recruiting	`NCT00370760` - Oral Colchicine Combined With Intravitreal Infusion of Dexamethasone, LMW Heparin and 5-FU for Management of Proliferative Vitreoretinopathy (PVR)	Phase 3
Completed	`NCT00000140` - The Silicone Study	Phase 3
Completed	`NCT06166914` - Efficacy of 5-fluorouracil and Low Molecular Weight Heparin in High-risk Pediatric Retinal Detachment	N/A
Recruiting	`NCT04580147` - Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Retinal Detachment Repair	Phase 2
Completed	`NCT04891991` - Intravitreal Infliximab for Proliferative Vitreoretinopathy	Phase 2
Completed	`NCT01255293` - Comparative Study of 1000 Centistoke Versus 5000 Centistoke Silicone Oil for Repair of Complex Retinal Detachments	N/A
Recruiting	`NCT06289205` - "Comparing Methotrexate Usage Techniques to Prevent Proliferative Vitreoretinopaty After Retinal Detachment Vitrectomy"	Phase 1/Phase 2
Completed	`NCT00373282` - Triamcinolone Acetonide in Silicone-Filled Eyes as Adjunctive Treatment for Proliferative Vitreoretinopathy	Phase 3
Completed	`NCT01995045` - Postoperative Pain Control Following Vitreoretinal Surgery	Phase 4
Completed	`NCT04490876` - Outcomes of Extensive Brilliant Blue G-Assisted Internal Limiting Membrane Peeling in Proliferative Vitreoretinopathy
Not yet recruiting	`NCT06425419` - The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy	Phase 1
Completed	`NCT02192970` - Bevacizumab Against Recurrent Retinal Detachment	Phase 2
Not yet recruiting	`NCT04682054` - Molecular Taxonomy of Surgically-harvested Ocular Tissues Defined by Single-cell Transcriptomics	N/A
Recruiting	`NCT05660447` - A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR	Phase 2/Phase 3
Not yet recruiting	`NCT06033703` - Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment	Phase 1/Phase 2
Active, not recruiting	`NCT00371020` - The Effect of 5-FU and LMW Heparin on the Rate of Retinal Redetachment After Silicone Oil Removal in Cases of PVR	Phase 3
Completed	`NCT03727776` - Adrenocorticotropic Hormone (ACTH) for Post-op Inflammation in Proliferative Vitreoretinopathy (PVR)	Early Phase 1

NCT number	NCT04136366
Study type	Interventional
Source	Aldeyra Therapeutics, Inc.
Contact
Status	Completed
Phase	Phase 3
Start date	November 15, 2019
Completion date	June 14, 2022

The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms